During the past decade, the biopharmaceutical industry in China has been transformed by government policies designed to support innovation and modernize drug discovery, development and review processes. Biopharmaceutical companies in China have used this support to create platforms for the development of highly sophisticated drugs such as antibody–drug conjugates (ADCs) and bispecific and multispecific antibodies.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
J.M.R. thanks Hanson Wade for access to the Beacon database, including the ADC and Bispecifics modules.
Competing Interests
J.M.R is an unpaid advisor for Beacon, which is part of Hanson Wade.
